Peptide therapy, prescribed clinically.
Vayra is a medical practice, not a marketplace. Peptide therapy is prescribed by your physician at a documented clinical encounter when it's appropriate for your specific case, never as an off-the-shelf product. Compounded by our 503A pharmacy partner against a patient-specific prescription. Guided by your labs, with transparent pricing and the total shown, so you know what you pay before you start.
What we treat with peptide therapy.
We don't publish a list of specific compounds on the public site. Whether peptide therapy is appropriate, and which preparation, is a clinical decision your physician makes after reviewing your labs and history.
Endocrine support
Therapies that support the hypothalamic-pituitary-gonadal (HPG) axis, often used alongside hormone therapy. Prescribed based on lab work and individual clinical picture.
Recovery & sleep architecture
Therapies that support tissue repair, growth-hormone-axis function, and the deep-sleep phases associated with recovery and consolidation. Patient-specific titration.
Cellular & metabolic
Therapies that support mitochondrial function, cellular energy production, and biomarkers commonly measured in lab-tracked care protocols. Always paired with quarterly labs.
Topical formulations
Compounded topical preparations for skin quality, post-procedure recovery, and collagen support. Prescribed when there's a documented indication.
Why our scope is what it is.
Vayra prescribes only peptide therapies that fall within established 503A clinical practice and have sufficient peer-reviewed safety evidence. We do not prescribe experimental or research-only peptides regardless of market demand or patient request. We follow regulatory and clinical-evidence updates, not trends.
We deliberately do not publish a list of specific compounds, either what we do prescribe or what we don't. That list itself creates the appearance of a menu, and Vayra is a medical practice, not a peptide marketplace. Your physician will explain what is and isn't part of your individual treatment plan at the visit.
Our scope follows FDA's 503A bulk-drug-substance framework and Vayra's internal Protocols Master. When that framework evolves, our scope evolves with it, never before formal reclassification, regardless of market pressure or patient demand.
Ready for a documented physician visit?
Prescribing is the outcome of a clinical encounter. Your assessment is eight minutes, physician-led, no insurance billing, currently expanding nationwide.